However, PSEN2 is also an attractive target to interrogate the biological heterogeneity of AD risk and AD-associated comorbidities, especially considering that hyperexcitability and seizures in people with PSEN2 variants are as common within 5 years of AD diagnosis as in people with APP duplications (3). This evidence concerns the gene APP and Alzheimer disease.